Caribou Biosciences, Inc. Files 2023 Annual Report on Form 10-K

TL;DR

<b>Caribou Biosciences, Inc. has filed its annual report detailing its 2023 financial performance and operations.</b>

AI Summary

Caribou Biosciences, Inc. (CRBU) filed a Annual Report (10-K) with the SEC on March 11, 2024. Caribou Biosciences, Inc. filed its 2023 Form 10-K on March 11, 2024. The company's fiscal year ends on December 31st. Caribou Biosciences is in the Biological Products industry. The company's business address is 2929 7th Street, Suite 105, Berkeley, CA 94710. The filing covers the fiscal year 2023.

Why It Matters

For investors and stakeholders tracking Caribou Biosciences, Inc., this filing contains several important signals. This 10-K filing provides a comprehensive overview of Caribou Biosciences' financial health, operational activities, and strategic direction for the fiscal year 2023, which is crucial for investors to assess the company's performance and future prospects. As a biotechnology company, understanding the details within this filing is essential for stakeholders to evaluate its progress in developing biological products and its overall market position.

Risk Assessment

Risk Level: — Caribou Biosciences, Inc. shows moderate risk based on this filing. The company is in the early stages of product development and has not yet generated significant revenue, indicating a high degree of financial risk associated with its research and development activities.

Analyst Insight

Investors should review the detailed financial statements and risk factors in the 10-K to assess the company's path to commercialization and potential for future revenue generation.

Key Numbers

• 2023-12-31 — Fiscal Year End (Reporting period end date)
• 2024-03-11 — Filing Date (Date the 10-K was filed)
• 2023 — Reporting Fiscal Year (The year covered by the report)

Key Players & Entities

• Caribou Biosciences, Inc. (company) — Filer name
• 2023 (date) — Fiscal year
• March 11, 2024 (date) — Filing date
• December 31 (date) — Fiscal year end
• 2929 7th Street, Suite 105, Berkeley, CA 94710 (address) — Business address
• 2836 (industry_code) — Standard Industrial Classification for Biological Products

FAQ

Industry Context

Caribou Biosciences operates in the biotechnology sector, specifically focusing on biological products. This industry is characterized by extensive research and development, regulatory oversight, and long product development cycles.

Regulatory Implications

Companies in the biological products sector are subject to stringent regulations from bodies like the FDA, governing product development, testing, and approval processes. Compliance is critical for market access.

What Investors Should Do

1. Review the full 10-K filing for detailed financial statements and management's discussion and analysis.
2. Analyze the company's risk factors section for potential challenges and uncertainties.
3. Investigate the company's product pipeline and development progress mentioned in the business overview.

Key Dates

• 2024-03-11: 10-K Filing — Annual report submission for fiscal year 2023.

Year-Over-Year Comparison

This is the initial 10-K filing for the fiscal year 2023. Comparative data from previous years will be available in subsequent filings.

Key Financial Figures

• $0.0001 — ich registered Common Stock, par value $0.0001 per share CRBU The Nasdaq Global Select

Filing Documents

• crbu-20231231.htm (10-K) — 2238KB
• ex1032-rachelx2024x02x20of.htm (EX-10.32) — 5KB
• ex1037-jasonx2024x02x20off.htm (EX-10.37) — 5KB
• ex1041-barbarax2024x02x20o.htm (EX-10.41) — 5KB
• ex1045-stevex2024x02x20off.htm (EX-10.45) — 5KB
• ex1049-ruhix2024x02x20offi.htm (EX-10.49) — 5KB
• ex1053-syedrizviseparation.htm (EX-10.53) — 122KB
• ex1054-timkellyofferletter.htm (EX-10.54) — 19KB
• ex1055-timkellyemploymenta.htm (EX-10.55) — 59KB
• ex211-listofsubsidiariesof.htm (EX-21.1) — 2KB
• ex231-consentofdeloittetou.htm (EX-23.1) — 3KB
• crbu-20231231xexx311.htm (EX-31.1) — 10KB
• crbu-20231231xexx312.htm (EX-31.2) — 10KB
• crbu-20231231xexx321.htm (EX-32.1) — 5KB
• crbu-20231231xexx322.htm (EX-32.2) — 5KB
• ex971-caribouxclawbackpoli.htm (EX-97.1) — 29KB
• crbu-20231231_g1.jpg (GRAPHIC) — 75KB
• crbu-20231231_g10.jpg (GRAPHIC) — 134KB
• crbu-20231231_g11.jpg (GRAPHIC) — 205KB
• crbu-20231231_g12.jpg (GRAPHIC) — 106KB
• crbu-20231231_g13.jpg (GRAPHIC) — 40KB
• crbu-20231231_g14.jpg (GRAPHIC) — 41KB
• crbu-20231231_g15.jpg (GRAPHIC) — 114KB
• crbu-20231231_g16.jpg (GRAPHIC) — 89KB
• crbu-20231231_g17.jpg (GRAPHIC) — 73KB
• crbu-20231231_g18.jpg (GRAPHIC) — 45KB
• crbu-20231231_g19.jpg (GRAPHIC) — 133KB
• crbu-20231231_g2.jpg (GRAPHIC) — 68KB
• crbu-20231231_g20.jpg (GRAPHIC) — 240KB
• crbu-20231231_g21.jpg (GRAPHIC) — 51KB
• crbu-20231231_g22.gif (GRAPHIC) — 238KB
• crbu-20231231_g23.jpg (GRAPHIC) — 429KB
• crbu-20231231_g24.jpg (GRAPHIC) — 140KB
• crbu-20231231_g25.jpg (GRAPHIC) — 94KB
• crbu-20231231_g26.jpg (GRAPHIC) — 107KB
• crbu-20231231_g3.jpg (GRAPHIC) — 84KB
• crbu-20231231_g4.jpg (GRAPHIC) — 48KB
• crbu-20231231_g5.jpg (GRAPHIC) — 66KB
• crbu-20231231_g6.jpg (GRAPHIC) — 77KB
• crbu-20231231_g7.jpg (GRAPHIC) — 465KB
• crbu-20231231_g8.jpg (GRAPHIC) — 131KB
• crbu-20231231_g9.gif (GRAPHIC) — 162KB
• image_0.jpg (GRAPHIC) — 34KB
• image_01.jpg (GRAPHIC) — 34KB
• image_02.jpg (GRAPHIC) — 34KB
• image_03.jpg (GRAPHIC) — 34KB
• image_04.jpg (GRAPHIC) — 34KB
• image_05.jpg (GRAPHIC) — 38KB
• image_06.jpg (GRAPHIC) — 193KB
• 0001619856-24-000013.txt (&nbsp;) — 19409KB
• crbu-20231231.xsd (EX-101.SCH) — 68KB
• crbu-20231231_cal.xml (EX-101.CAL) — 94KB
• crbu-20231231_def.xml (EX-101.DEF) — 328KB
• crbu-20231231_lab.xml (EX-101.LAB) — 828KB
• crbu-20231231_pre.xml (EX-101.PRE) — 613KB
• crbu-20231231_htm.xml (XML) — 1254KB

Business

Business 1 Item 1A.

Risk Factors

Risk Factors 52 Item 1B. Unresolved Staff Comments 104

C

Item 1 C . Cybersecurity 105 Item 2.

Properties

Properties 106 Item 3.

Legal Proceedings

Legal Proceedings 106 Item 4. Mine Safety Disclosures 106 PART II Item 5. Market for Registrant's Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities 107 Item 6. [Reserved ] 107 Item 7.

Management's Discussion and Analysis of Financial Condition and Results of Operations

Management's Discussion and Analysis of Financial Condition and Results of Operations 108 Item 7A.

Quantitative and Qualitative Disclosures About Market Risk

Quantitative and Qualitative Disclosures About Market Risk 122 Item 8.

Financial Statements and Supplementary Data

Financial Statements and Supplementary Data 122 Item 9. Changes in and Disagreements with Accountants on Accounting and Financial Disclosure 122 Item 9A.

Controls and Procedures

Controls and Procedures 122 Item 9B. Other Information 123 Item 9C. Disclosure Regarding Foreign Jurisdictions that Prevent Inspections 123 PART III Item 10. Directors, Executive Officers and Corporate Governance 124 Item 11.

Executive Compensation

Executive Compensation 124 Item 12.

Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters

Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters 124 Item 13. Certain Relationships and Related Transactions, and Director Independence 124 Item 14. Principal Accounting Fees and Services 124 PART IV Item 15. Exhibits, Financial Statement Schedules 125 Item 16. Form 10-K Summary 125 i Table of Contents Risk Factors Summary Our business is subject to a number of risks of which you should be aware before making a decision to invest in our common stock. These risks are more fully described in the "Risk Factors" section in Part I, Item 1A of this Annual Report on Form 10-K. These risks include, among others, the following: We have incurred significant operating losses since our inception and anticipate that we will incur continued operating losses for the foreseeable future and may not be able to achieve or sustain profitability. We will need substantial additional financing to develop our product candidates and implement our operating plans. If we fail to obtain additional financing, we may be delayed or unable to complete the development and commercialization of our product candidates. We have a limited operating history, which may make it difficult to evaluate our technologies and product candidate development capabilities or to predict our future performance. We are early in our development efforts and it will be many years before we commercialize a product candidate, if ever. If we are unable to advance our product candidates through clinical trials, obtain regulatory approval, and ultimately commercialize our product candidates, or we experience significant delays in doing so, our business will be materially harmed. Our product candidates are cell therapies generated by our novel CRISPR chRDNA genome-editing technologies, which make it difficult to predict the time and cost of developing these product candidates and obtaining regulatory approval. To date, no other products that use these

Business

Item 1. Business. Overview We are a clinical-stage C lustered R egularly I nterspaced S hort P alindromic R epeats ("CRISPR") genome-editing biopharmaceutical company dedicated to developing transformative therapies for patients with devastating diseases. Our genome-editing platform, including our novel chRDNA ( C RISPR h ybrid R NA- DNA , or "chRDNA," pronounced "chardonnay") technology, enables more precise genome editing to develop cell therapies that are armored to improve activity against diseases. We are advancing a pipeline of allogeneic, or off-the-shelf, cell therapies from our chimeric antigen receptor ("CAR") -T ("CAR-T") cell and CAR-natural killer ("CAR-NK") cell platforms as readily available therapeutic treatments for patients. We are initially focused on advancing our allogeneic cell therapies for the treatment of hematologic malignancies. Our therapies are directed at established cell surface targets for which autologous CAR-T cell therapeutics have already demonstrated clinical proof of concept, including CD19 and B cell maturation antigen ("BCMA"), as well as targets such as C-type lectin-like molecule-1 ("CLL-1," also known as CD371). We use our chRDNA technologies to armor our cell therapies through multiple genome-editing strategies, such as checkpoint disruption, immune cloaking, or a combination of these two strategies, to enhance activity against devastating diseases. Our Pipeline Our pipeline includes three clinical-stage allogeneic cell therapies from our CAR-T cell platform targeting the treatment of hematologic malignancies. Our pipeline is shown below: * Also known as CD371 Figure 1 . We are developing a pipeline of three clinical-stage allogeneic CAR-T cell therapies for the treatment of hematologic malignancies. Our Programs Our lead product candidate, CB-010, is an allogeneic CAR-T cell therapy that is, to our knowledge, the first anti-CD19 allogeneic, or off-the-shelf, CAR-T cell therapy to be evaluated in patients wit

View Full Filing

View this 10-K filing on SEC EDGAR